Pandemic preparedness: Newcastle disease virus-vectored vaccine against HPAI H5

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 507215

Grant search

Key facts

  • Disease

    Influenza caused by Influenza A virus subtype H5
  • start year

    2024
  • Known Financial Commitments (USD)

    $108,869.54
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Susta Leonardo
  • Research Location

    Canada
  • Lead Research Institution

    University of Guelph
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Over the past decade, highly pathogenic avian influenza virus strains from Eurasia have increasingly spread to North America, causing severe outbreaks in poultry and posing a threat to humans. A new influenza H5N1 virus reached Eastern Canada in late 2021 via migratory birds. This virus has adapted to local wildlife, becoming endemic in wild birds in North America. It has also been shown to infect various mammals, including ruminants like goats and dairy cows, where it accumulates at high concentration in udder and milk. This broad host range increases the risk of human infection. As these viruses become more common in farm animals, there is growing support for livestock vaccination, which can improve animal welfare and protect human health by reducing virus spread. Our proposal aims to test a new vaccine using a non-virulent Newcastle disease virus (NDV) to deliver a component of the influenza virus (the H5 gene) to promote antibody development in chickens, ducks, and sheep (as a model for dairy cows). This vaccine can be administered through mucosal routes, like sprays or drinking water, making mass vaccination easier. We plan to develop three NDV vaccine candidates expressing different versions of the H5 gene. We will first test these candidates for effectiveness in hamsters and chickens. The best candidate will then be tested in chickens and ducks to see if it can protect against H5N1 infection and transmission. Lastly, we will test the vaccine's effectiveness in lactating sheep, specifically focusing on antibody release in milk. This research will help Canada prepare for H5N1 outbreaks by developing an effective vaccine. It will also provide important data to guide policies on livestock vaccination, potentially reducing virus transmission. The project involves collaboration between the University of Guelph, the University of Toronto, the Canadian Food Inspection Agency, and the Ontario Ministry of Agriculture, Food and Rural Affairs.